| Do firms underinvest in long-term research? Evidence from cancer clinical trials E Budish, BN Roin, H Williams Am. Econ. Rev. 105 (7), 2044-2085, 2013 | 441 | 2013 |
| Unpatentable drugs and the standards of patentability BN Roin Texas Law Review 87, 503-570, 2009 | 354 | 2009 |
| Intellectual property versus prizes: Reframing the debate BN Roin The University of Chicago Law Review, 999-1078, 2014 | 166 | 2014 |
| The disclosure function of the patent system (or lack thereof) BN Roin Harvard University, Harvard Law School, 2005 | 150 | 2005 |
| The case for tailoring patent awards based on time-to-market BN Roin UCLA Law Review 61 (3), 672-759, 2014 | 127 | 2014 |
| Medicines for the mind: policy-based “pull” incentives for creating breakthrough CNS drugs DW Choi, R Armitage, LS Brady, T Coetzee, W Fisher, S Hyman, A Pande, ... Neuron 84 (3), 554-563, 2014 | 82 | 2014 |
| Patents and research investments: Assessing the empirical evidence E Budish, BN Roin, H Williams American Economic Review 106 (5), 183-187, 2016 | 75 | 2016 |
| Do fixed patent terms distort innovation?: Evidence from cancer clinical trials EB Budish, BN Roin, HL Williams Evidence from Cancer Clinical Trials (September 5, 2013). Chicago Booth …, 2013 | 59 | 2013 |
| Solving the problem of new uses BN Roin Available at SSRN 2337821, 2013 | 31 | 2013 |
| Causal inference on patent protection JM Kuhn, BN Roin, NC Thompson Working Paper, 2016 | 7 | 2016 |
| Drug patent length BN Roin mimeo, Harvard Law School, 2010 | 7 | 2010 |
| Solving the problem of new uses by creating incentives for private industry to repurpose off-patent drugs BN Roin Mich St L Rev. http://petrieflom. law. harvard. edu/assets/publications/Roin …, 2014 | 6 | 2014 |
| DON'T MISS THESE GREAT FEBRUARY EVENTS! J DiGiacinto, RS Langer, B Roin University of Pennsylvania Law Review 165 (2), 2017 | | 2017 |
| Do firms underinvest in long-term research? Evidence from cancer clinical trials Online appendix E Budish, BN Roin, H Williams | | 2015 |
| Introduction, Regulatory Exclusivities and the Regulation of Generic Drugs and Biosimilars BN Roin FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New …, 2015 | | 2015 |
| Online Appendix for: Patents and Research Investments: Assessing the Empirical Evidence E Budish, BN Roin, H Williams | | |
| Measuring Patent Scope JM Kuhn, BN Roin, NC Thompson | | |
Eric BudishPaul G. McDermott Professor of Economics and Entrepreneurship, Chicago Boothایمیل تأیید شده در chicagobooth.edu